Abstract

Background: Benign prostate hyperplasia (BPH) is a commondisease in elderly men. The purpose of this study is to evaluate the clinical value of miR-4428 in senile BPH, aiming to identify a novel and effective biomarker for BPH.

Methods: The study included 120 patients with BPH and 120 healthy individuals (controls). Expression levels of miR-4428 were measured with RT-qPCR. The risk factors of senile BPH were conducted by logistic regression analysis, and ROC curves were utilized to determine the diagnosis value of miR-4428 in of BPH. CCK8 and flow cytometric were used to study the proliferation and apoptosis of prostate cells. The oxidative stress response of BPH cellswas evaluated by measuring malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione (GSH) levels.

Results: miR-4428 is upregulated in senile BPH patients and exhibits the ability to distinguish BPH from healthy individuals, demonstrating high sensitivity (83.33%) and specificity (71.67%). Upregulation of miR-4428 may be a predictive marker in senile BPH. Furthermore, a significant increase in miR-4428 was observed in BPH-1 cells than in WPMY-1 cells. This trend was reversed upon transfection with miR-4428 inhibitors, resulting in decreased proliferation rate and increased apoptosis rate of cells. Notably, BPH induces oxidative stress, which leads to increased levels of MDA and decreased levels of SOD and GSH, which can be reversed by transfection with miR-4428 inhibitors.

Conclusion: miR-4428 can differentiate between senile BPH patients and healthy individuals with high sensitivity and specificity, making it a valuable a diagnostic biomarker for BPH.